Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF‐V600E‐positive non–small cell lung cancer: A case report

Dabrafenib plus trametinib is the standard treatment for BRAF V600E‐mutated non‐small cell lung cancer. No treatment‐related cerebral infarction (CI) has been reported in previous clinical trials. Here, we described a 61‐year‐old Japanese man with BRAF V600E‐mutated lung adenocarcinoma treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Taniguchi, Yoshihiko, Tamiya, Akihiro, Yanagisawa, Atsushi, Shimaya, Minako, Kawakami, Mayu, Inagaki, Yuji, Saijo, Nobuhiko, Matsuda, Yoshinobu, Okishio, Kyoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151131/
https://www.ncbi.nlm.nih.gov/pubmed/36935386
http://dx.doi.org/10.1111/1759-7714.14852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151131/
https://www.ncbi.nlm.nih.gov/pubmed/36935386
http://dx.doi.org/10.1111/1759-7714.14852

Ejemplares similares